Hahn Offers Upbeat User-Fee Prediction At AdvaMed Conference
Executive Summary
The US FDA commish praised the medical device community's work in response to the COVID-19 pandemic and predicted that communication developed with industry during the crisis may ease upcoming MDUFA negotiations.
You may also be interested in...
FDA Makes 2nd Attempt At Virtual MDUFA Public Meeting
For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.